Chinese herbal medicine can significantly reduce the risks of complications and need for surgery associated with benign prostatic hyperplasia.
Cohort Study Benign Prostatic Hyperplasia Dan Shen Ji Sheng Shen Qi Wan
The methodology of the retrospective cohort study involved analyzing data from Taiwan's National Health Insurance Research Database, covering the period between 2001 to 2013. 4142 patients newly diagnosed as having benign prostatic hyperplasia were divided into Chinese herbal medicine users and non-users. To compare these groups, they employed 1:1 propensity score matching, and the risk of complications related to benign prostatic hyperplasia was evaluated using the Cox proportional hazard model.
The results showed that during the study period, the risk of complications related to benign prostatic hyperplasia was considerably lower in the Chinese herbal medicine group compared to the non-Chinese herbal medicine group, even when other variables were controlled for. The Chinese herbal medicine users had a significantly lower risk of urinary tract infection and urine retention. Plus, the Chinese herbal medicine users experienced a lower incidence rate of surgery related to benign prostatic hyperplasia and enjoyed a longer surgery-free interval than non-Chinese herbal medicine users. Among the Chinese herbal medicine, Salviae miltiorrhizae and Ji-Sheng-Shen-Qi-Wan were prescribed the most by traditional Chinese medicine practitioners.
View Article
Salvia miltiorrhiza Bunge (SM) and Ji-Sheng-Shen-Qi-Wan (JSSQW) were the most frequent single herb and formula, respectively, prescribed for patients with CKD. The most frequent CHM combination between herbs and formulas was JSSQW, associated with Rheum officinale Baill. (RO), SM and Astragalus membranaceus (Fisch.) Bunge (AM).
—Jinnan C 26 Dec 2023